Skin Disorders News

Clinical and economic factors make hereditary angioedema difficult to diagnose and treat, particularly among patients who live in rural areas, according to a study published in Annals of Allergy, Asthma & Immunology.

Older patients with chronic urticaria have characteristics that are unique compared with younger patients, such as high rates of autoimmunity and malignancy, according to a study.

Patients with atopic dermatitis treated with dupilumab did not experience any significantly increased risk for a primary or recurrent malignancy, according to a study published in The Journal of Allergy and Clinical Immunology: In Practice.

Our Food Allergy: Fact vs. Fiction column and research presented at the 2023 American Academy of Allergy, Asthma & Immunology Annual Meeting in San Antonio dominated our list of the most read stories in allergy and asthma for March.

The Pfizer-BioNTech BNT162b2 COVID-19 vaccine was not associated with any risk for adverse reactions among children with chronic urticaria, according to a study published in The Journal of Allergy and Clinical Immunology: In Practice.

The use of topical corticosteroids to treat atopic dermatitis in infants also may help prevent hen’s egg allergy, but it may inhibit the baby’s growth as well, according to a study published in The Journal of Allergy & Clinical Immunology.

SAN ANTONIO — Remibrutinib displayed sustained efficacy for chronic spontaneous urticaria with a favorable safety profile over 52 weeks, according to data presented at the American Academy of Allergy, Asthma & Immunology Annual Meeting.

Two phase 3 trials found that lebrikizumab was effective against moderate-to-severe atopic dermatitis in adolescents and adults, researchers reported in The New England Journal of Medicine.

NEW ORLEANS — Although Black patients with atopic dermatitis treated with dupilumab experienced fewer adverse events than their white counterparts, the difference did not reach statistical significance, according to a poster presented here.

SAN ANTONIO — Insurance delays and denials for hereditary angioedema medication have a negative impact on physical and mental health, according to data presented at the American Academy of Allergy, Asthma & Immunology Annual Meeting.